Skip to content

Study · Observational study · n = 30 · 2017

6 results

Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study.

Muin DA, Sheikh Rezaei S, Tremmel-Scheinost M, Salama M, Luger A, Wolzt M, Husslein PW, Bayerle-Eder M

Fertility and sterility8 Feb 2017Cited by 7 (Europe PMC)

PMID28189292 (opens in a new tab)DOI10.1016/j.fertnstert.2016.12.003 (opens in a new tab)PepBankPUB-28189292
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, the Sexual Life Quality questionnaire improved significantly from baseline both when the women used oxytocin nasal spray and when they used placebo.

    In plain wordsIn male partners of women with low sexual desire, sexual life quality scores rose from baseline with both oxytocin spray and placebo spray.

    Peptide
    Oxytocin
    Outcome
    IncreaseMale Sexual Life Quality questionnaire
    Study

    n = 30

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Male Sexual Life Quality questionnaire improved significantly from -7.4 ± 9.9 at baseline to 8.2 ± 12 with female partners' treatment with oxytocin nasal spray and to 10.8 ± 13.8 with placebo.
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.
  2. 02HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, the men's evaluation of their partner's performance improved significantly from baseline both with the women's oxytocin treatment and with placebo.

    In plain wordsIn male partners of women with low sexual desire, ratings of their partner's performance rose from baseline with both oxytocin and placebo spray.

    Peptide
    Oxytocin
    Outcome
    IncreaseEvaluation of female partner's performance
    Study

    n = 30

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Evaluation of female partners' performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 with oxytocin and to 11.2 ± 2.6 with placebo.
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.
  3. 03HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, male satisfaction and Hamilton Depression Scale scores showed only nonsignificant improvement.

    In plain wordsIn male partners of women with low sexual desire, satisfaction and depression scores improved only slightly, and not significantly.

    Peptide
    Oxytocin
    Outcome
    No significant changeMale satisfaction and Hamilton Depression Scale
    Study

    n = 30

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    A nonsignificant improvement was seen in the frequency of intercourse, male arousal, desire, satisfaction, and Hamilton depression scale
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.
  4. 04HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, the frequency of intercourse improved slightly but not significantly from baseline with the women's oxytocin therapy.

    In plain wordsIn male partners of women with low sexual desire, intercourse frequency rose slightly from baseline with the women's oxytocin spray, but not significantly.

    Peptide
    Oxytocin
    Outcome
    No significant changeFrequency of intercourse
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Frequency of intercourse improved slightly but not significantly from 6.3 ± 3.9 at baseline to 7.3 ± 4 with female oxytocin therapy, but not with placebo.
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.
  5. 05HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, male desire and arousal remained stable throughout the study period.

    In plain wordsIn male partners of women with low sexual desire, the men's desire and arousal stayed stable during the study.

    Peptide
    Oxytocin
    Outcome
    No significant changeMale desire and arousal
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Male desire and arousal remained stable throughout the study period.
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.
  6. 06HumanObservational studyEfficacy outcome

    In male partners of women with HSDD, there was no difference between the women's oxytocin and placebo treatment on any male outcome parameter.

    In plain wordsIn male partners of women with low sexual desire, oxytocin spray gave no different results from placebo spray on any outcome.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin versus placebo on all male outcome parameters
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IE · nasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Female treatment with either oxytocin or placebo for HSDD significantly improves male sexual quality of life and evaluation of female partner's sexual performance with no difference between oxytocin and placebo on any outcome parameters.
    2 context sentences
    Summary · context
    Open prospective cohort study of 22 weeks.
    Summary · context
    Male partners of 30 premenopausal and postmenopausal women with HSDD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02229721

Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women

Medical University of Viennan = 30Jun 2012 to Oct 2013

Female Sexual Dysfunction

Trial pageClinicalTrials.govUpdated 1 Sept 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.